Source comparison
Tesamorelin Before and After: Comparison Across Protocols and Populations
The following table compares tesamorelin before and after outcomes across different dosing protocols, populations, and intervention durations based on published trial data and observational cohorts. Tesamorelin 2mg daily (HIV lipodystrophy) 26 weeks −15.2% (−3
This comparison does not assign a generated winner or score.
- The following table compares tesamorelin before and after outcomes across different dosing protocols, populations, and intervention durations based on published trial data and observational cohorts.
- Tesamorelin 2mg daily (HIV lipodystrophy)
- 26 weeks
- −15.2% (−32.5 cm²)
- −1.8 kg
- −2.1 cm
- Gold standard protocol. Consistent VAT reduction with minimal systemic weight loss; ideal for visceral adiposity without appetite suppression
- Tesamorelin 2mg daily (non-HIV metabolic syndrome)
- −12.8% (−28 cm²)
- −2.3 kg
- −1.9 cm
- Slightly lower VAT response in non-HIV populations, possibly due to lower baseline VAT volumes; still clinically significant for cardiometabolic risk reduction
- Tesamorelin 1mg daily (dose-finding trial)
- −8.1% (−18 cm²)
- −0.9 kg
- −1.1 cm
- Suboptimal dosing. Produces measurable VAT reduction but falls short of therapeutic threshold; not recommended for clinical use
- Tesamorelin 2mg + caloric deficit (−300 kcal/day)
- −22.4% (−48 cm²)
- −4.6 kg
- −3.8 cm
- Combining tesamorelin with modest caloric restriction amplifies VAT reduction and produces greater waist circumference change; synergistic rather than additive effect
- Tesamorelin discontinued after 26 weeks
- Follow-up 12 weeks post-cessation
- +12.3% VAT regain from nadir
- +1.4 kg
- +1.6 cm
- Visceral fat reaccumulation begins within 8 weeks of stopping; approximately 70% of VAT reduction is lost by week 12 post-treatment
- Tesamorelin 2mg continuous (52-week extension)
- 52 weeks
- −18.7% (−41 cm²)
- −2.4 kg
- −2.6 cm
- VAT reductions plateau between weeks 26 and 52; continued dosing maintains effect but does not produce further meaningful reduction beyond 20%